Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01560429
Other study ID # ANAE-147-08
Secondary ID ANAE-147-08
Status Completed
Phase Phase 4
First received March 6, 2012
Last updated March 21, 2012
Start date June 2009
Est. completion date July 2010

Study information

Verified date March 2012
Source Queen's University
Contact n/a
Is FDA regulated No
Health authority Canada: Canadian Institutes of Health Research
Study type Interventional

Clinical Trial Summary

Postoperative thoracotomy pain is normally managed with an epidural catheter and continuous epidural analgesia (CEA). However, for some surgical procedures, patient controlled epidural anesthesia (PCEA) is more effective but little research has compared the two methods following thoracotomy. The current randomized, prospective clinical investigation did just this. Following institutional ethics approval 47 patients scheduled for thoracotomy were recruited for this prospective, randomized, unblinded study. A thoracic epidural catheter was sited preoperatively. Postoperatively patients were randomized to receive epidural infusions (hydromorphone 10 mcg/mL + bupivacaine 1 mg/mL) for 48 hours postoperatively via PCEA (n= 24) or CEA (n=23). CEA infusion rates were titrated to achieve pain scores ≤ 3 out of 10 (numeric rating scale (NRS)) in the recovery room. PCEA parameters were adjusted to allow an equivalent dose per hour. The primary outcome was consumption of local anaesthetic/opioid. The secondary outcomes were worst pain and pain while coughing (0-10 NRS).


Recruitment information / eligibility

Status Completed
Enrollment 74
Est. completion date July 2010
Est. primary completion date July 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- 18-75 years of age

- American Society of Anesthesiologist's (ASA) Physical Status I-III

- Body Mass Index (BMI) < 40

- Able to use a PCEA device

Exclusion Criteria:

- Intolerance/hypersensitivity to agents used in the study

- Contraindication to epidural placement

- Current alcohol/substance abuse

- Chronic pain condition requiring chronic analgesic

- BMI = 40 or body weight less than 50kg.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Patient controlled epidural analgesia
CEA infusion rates were set when pain scores of = 3 on a numeric rating scale (NRS) of 0 to 10 were achieved in PACU. PCEA parameters were adjusted to allow an equivalent dose per hour. Use of hydromorphone 20 mcg/ml and bupivacaine 1 mg/ml (20 and 1) or hydromorphone 10 mcg/ml and bupivacaine 2 mg/ml (10 and 2) was permitted to achieve pain scores = 3. Rescue boluses of 0.25% bupivacaine of 3 to 5 cc to a maximum of 10 cc were also permitted to achieve pain scores of less than 3 in PACU. Total consumption includes rescue medications as well as any switch in anesthetic concentration.
Continuous epidural analgesia
The CEA infusion rates were set when pain scores of = 3 on a numeric rating scale (NRS) of 0 to 10 were achieved in PACU. PCEA parameters were adjusted to allow an equivalent dose per hour. Use of hydromorphone 20 mcg/ml and bupivacaine 1 mg/ml (20 and 1) or hydromorphone 10 mcg/ml and bupivacaine 2 mg/ml (10 and 2) was permitted to achieve pain scores = 3. Rescue boluses of 0.25% bupivacaine of 3 to 5 cc to a maximum of 10 cc were also permitted to achieve pain scores of less than 3 in PACU. Total consumption includes rescue medications as well as any switch in anesthetic concentration.

Locations

Country Name City State
Canada Kingston General Hospital Kingston Ontario

Sponsors (1)

Lead Sponsor Collaborator
Queen's University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Local anesthetic consumption Amount of anesthetic consumed (either through epidural catheter or as rescue bolus at 4, 8, 12, 24 and 48 hours following thoracotomy administered either through CEA or PCEA. 48 hours postoperatively No
Secondary worst pain scores worst pain scores on numerical rating scale (0-10, where 10 is the worst) at 24 & 48 hours following surgery 48 hours postoperatively No
Secondary Worst pain while coughing Worst pain on a numberical rating scale(0-10 worst) at 24 and 48 horus following thoracotomy 48 hours postoperatively No
See also
  Status Clinical Trial Phase
Recruiting NCT03538340 - Intraoperative Cryoanalgesia for Extended Pain Management Following Thoracotomy N/A
Completed NCT02397603 - Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine Induced Paravertebral Block in Patients Undergonig Thoracotomy Phase 2
Recruiting NCT04209868 - Preoperative Paravertebral Block in Cancer Surgery of the Lung Phase 2/Phase 3
Recruiting NCT04726930 - Ultrasound Needle Transducer for Regional Anesthesia Validation Study